Research Progress of STAT3 Signaling Pathway in Triple Negative Breast Cancer

GAO Shuo^1,2, WANG Jinhua^1,2*

(¹Graduate School of Inner Mongolia Medical University, Hohhot 010059, China; ²Department of Pathology, Tumor Hospital of Inner Mongolia Autonomous Region, Hohhot 010020, China)

Abstract:

TNBC (triple negative breast cancer), which lacks expression of hormone receptor and amplification the gene of HER2 (human epidermal growth factor receptor 2), is one subtype of breast cancer. As it can not be treated by hormone therapy or anti-HER2 drugs, it has the characteristics of easy metastasis, high recurrence rate, low survival rate and poor prognosis. At present, the treatment for TNBC patients relies on conventional chemotherapy, so it is urgent to find new therapeutic targets. Studies have shown that STAT3 (signal transducers and activators of transcription 3) may participate in the occurrence, progression, invasion and metastasis, angiogenesis and drug resistance of TNBC. In addition, a new path of interaction composed of upstream regulator and downstream target of STAT3 is found. This article aims to explore the regulatory mechanism of STAT3 in TNBC and its application prospect as a therapeutic target.

CSTR: 32200.14.cjcb.2020.12.0018